Phenelzine (Nardil)
What studies of Phenelzine (Nardil) found
At a glance, by condition
ME/CFS: D Little or no difference
Based on the strongest evidence, the placebo trial (very low certainty): 2 findings, all D.
2 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with Phenelzine (Nardil) for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Phenelzine (Nardil) · ME/CFS is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Daily life and health overall
Daily functioning1 study · 9 (few people) people took Phenelzine (Nardil) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 18 people found no clear difference; a small benefit can't be ruled out.
The placebo trial18 analysed · 6 weeks (three 2-week phases; measures at time A, time B and time C, 1 month later) · 15 mg, one 15-mg pill per day alternating with placebo during the second 2-week period
No clear difference in daily functioning.
The evidence is very uncertain about the effect of phenelzine (Nardil) on daily functioning in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 18 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 18 analysed
- Dose
- 15 mg, one 15-mg pill per day alternating with placebo during the second 2-week period
- Outcome
- FSQ functional status questionnaire
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Overall symptoms1 study · 9 (few people) people took Phenelzine (Nardil) Little or no difference D
Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 18 people found no clear difference; a small benefit can't be ruled out.
The placebo trial18 analysed · 6 weeks (three 2-week phases; measures at time A, time B and time C, 1 month later) · 15 mg, one 15-mg pill per day alternating with placebo during the second 2-week period
No clear difference in overall symptoms.
The evidence is very uncertain about the effect of phenelzine (Nardil) on overall symptoms in ME/CFS. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 18 people found no clear difference; a small benefit can't be ruled out
See the 1 study
-
- People in the study
- 18 analysed
- Dose
- 15 mg, one 15-mg pill per day alternating with placebo during the second 2-week period
- Outcome
- variables tested
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
15 mg at the start
- 2Top dose
Most often 15 mg (1 of 1 studies)
Doses across 1 study
15 to 15 mg.
Each study’s dose, as printed
- 15 mg, one 15-mg pill per day alternating with placebo during the second 2-week period Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. (1996)
All papers
- Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome.1996 · placebo trial · 18 analysed
Summary
Researchers studied patients from a University CFS Center who met the 1988 case definition of chronic fatigue syndrome, to test whether low-dose phenelzine would reduce symptoms and whether a placebo effect would be seen. The randomized, double-blind, placebo-controlled trial lasted 6 weeks in three 2-week phases. The phenelzine group received placebo, then 15 mg phenelzine every other day, then 15 mg daily; the placebo group took one placebo pill per day. Eighteen patients were analyzed, nine in each group. Measures were 20 self-report tests covering functional status, mood, illness severity, fatigue and symptoms. No significant differences were found for any individual variable. In a pattern analysis, 11 tests showed a plurality of drug-treated patients improving and none worsening, versus five improving and four worsening with placebo (P = 0.037); among the remaining ten tests, nine versus five showed improvement. On the POMS depression component, 43% of drug-treated and 56% of placebo-treated patients improved; on the CES-D, 67% and 75% improved. For placebo effect, one of 20 tests showed improvement (P < 0.04), and other analyses found no significant placebo effect; nine of 18 patients had higher symptom scores at point B than at point A, while six reported fewer. Six phenelzine patients did not complete the trial: one for unreliability, two during placebo phase-in, and three because of unpleasant symptoms on 15 mg phenelzine daily. The authors caution that the pattern finding had no individual-measure improvement and ignored magnitude of effect.
- A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.2016 · systematic review
Summary
This systematic review examined drug therapies for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME). Ovid MEDLINE, EMBASE, and PubMed were searched from the beginning of their archives to March 2016. The review included 26 randomized, placebo-controlled trials that met its criteria; these trials tested 20 drug therapies. The review reports effectiveness by categories from not effective to highly effective and says no universal pharmaceutical treatment can be recommended. Hydrocortisone findings were conflicting: across studies it was reported as mildly effective, slightly effective, not effective, and moderately effective; in one study the well-being improvement was not significant, and Blockmans et al found no clinical improvement. Rituximab was reported to produce a significant and lasting improvement, but the review states it is premature to conclude a lasting improvement in primary assessed domains; primary end points were evaluated for 3 months and secondary end points up to 12 months. For intravenous immunoglobulin, Rowe reported headache, fatigue, and difficulty concentrating significantly worse in the intervention group after the first infusion, with no differences after the third and final infusion. The review states no pharmaceutical therapy resulted in severe adverse events. It notes nefazodone was discontinued in 2004 after patients developed hepatic and visual disorders. Forsyth et al and Young each had N = 26; Young lacked male participants in the intervention cohort. The authors state that no clear recommended pharmaceutical therapy for CFS/ME exists and call for standardized diagnostic criteria and outcome measurements.
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
Summary
This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.
- Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
Summary
This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).
- Treating chronic fatigue syndrome - a study into the scientific evidence for pharmacological treatments.2011 · review
Summary
The paper reports a questionnaire survey of 94 CFS patients from Queensland and New South Wales, recruited through support groups and newspaper and email advertisements, plus a search for randomised controlled trials. Patients filled out a questionnaire on current medicines and supplements; no treatment was given by the authors, and the survey had no comparison group. The 94 patients used 474 different medicines and supplements. Commonly used were antidepressants (41%), sedatives (27%), B vitamins (47%), magnesium (24%) and co-enzyme Q10 (7%). The search identified 20 RCTs. Findings included no difference for fluoxetine on fatigue or SF-36, no difference between treatment and placebo on individual questionnaires, and no effect for several agents including phenelzine, moclobemide, valaciclovir, terfenadine, melatonin, ginseng, bovine liver extract and a polynutrient supplement. One hydrocortisone trial reported 87% rated themselves improved versus 17% on placebo (p<0.001); another reported 53% vs. 29% (p=0.04) improvement in wellness score. Harm notes included diarrhoea with high-dose oral magnesium, long-term adrenal gland suppression with adrenal hormones, addiction and loss of effectiveness with benzodiazepines and opiates, and hormonal/lipid changes with DHEA. No worsening or stopping was reported. The authors state limitations.
- Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
Summary
This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.
- Antidepressants and cognitive-behavioral therapy for symptom syndromes.2006 · review
Summary
This review article examined antidepressant medications and cognitive-behavioral therapy for 11 somatic syndromes, including chronic fatigue syndrome. It did not report its own enrolments, analysed patients, setting, or follow-up; patient counts were not reported. The review described trials of antidepressants versus placebo and trials of CBT. Outcomes included global symptoms, pain, sleep, fatigue, mood, and energy. For CFS, the review reports that a systematic review found two interventions beneficial for improving but not curing symptoms: CBT and graded exercise. It reports that six of the seven RCTs of CBT on CFS found benefit, with an effect lasting for 5 years. Among antidepressant trials, two fluoxetine trials showed no benefit other than for depressive symptoms; one phenelzine trial showed improvement in multiple CFS symptoms, illness severity, and mood; and a moclobemide trial showed improvement in subjective vigor and energy. The review reports mixed evidence that antidepressants lead to overall improvement and states there is no randomized trial evidence demonstrating any efficacy for methylphenidate. The authors state that evidence for antidepressants in CFS is limited and insufficient for convincing conclusions.
- Chronic fatigue syndrome in the psychiatric practice.2002 · review
Summary
This REVIEW ARTICLE concerns chronic fatigue syndrome (CFS) and reviews treatments for CFS, reporting cited trials rather than a new study. Vercoulen contrasted fluoxetine with placebo in 96 patients and did not find any significant effect on fatigue complaints or depression complaints. Wearden examined fluoxetine, placebo and physical exercise in 136 patients; fluoxetine gave a significant improvement of depression scores but a non-significant improvement of fatigue complaints, while physical exercise appeared to result in a significant improvement of fatigue complaints. Natelson studied phenelzine against placebo in 24 patients and found an improvement of fatigue complaints compared with placebo. Behan found a superior antidepressant effect of sertraline vs clomipramine in 40 patients, with no placebo group. Deale reported at final follow-up that 70% of the CBT group achieved a substantial improvement in physical functioning, compared with 19% of the relaxation group. Reference 38 found the number of patients showing clinical improvement was not significantly higher with hydrocortisone than with placebo; reference 39 showed a significant reduction in self-reported fatigue scores with hydrocortisone compared with placebo. Higher doses of cortisone in one study caused adrenal suppression in 40% of patients participating in active treatment. The authors conclude that antidepressants do not seem to have a positive influence on fatigue but appear beneficial for depression and social functioning; CBT and graded exercise show significant improvement and are the only treatments available for CFS patients; glucocorticoid therapy is not recommendable as a standard treatment. Limitations are not reported.
- Chronic fatigue syndrome.2000 · review
Summary
Clinical review searched January 1999 for randomised controlled trials of treatments for chronic fatigue syndrome. It assessed antidepressants, corticosteroids, exercise, prolonged rest, dietary supplements, immunotherapy, cognitive behavioural therapy, and oral nicotinamide adenine dinucleotide. In antidepressants, one RCT compared fluoxetine with placebo in 96 people and found no significant benefit; another allocated 136 people to exercise plus fluoxetine, exercise plus placebo, appointments plus fluoxetine, or appointments plus placebo and found no significant difference in fatigue. In corticosteroids, a trial in 32 people found nine people (28%) taking hydrocortisone improved compared with three (9%) taking placebo; a 65-person hydrocortisone trial found greater improvement on a self-rated wellness scale but other self-rating scales did not show significant benefit. In exercise, an RCT in 66 people reported 55% of the aerobic exercise group much better or very much better compared with 27% of the flexibility training group; a 136-person trial found exercise associated with significant improvements in fatigue and functional work capacity. CBT trials: in 60 people, 73% receiving CBT improved compared with 27% receiving standard care; in another 60 people, 63% had a good outcome with CBT compared with 17% with relaxation therapy. An IgG trial randomised 49 patients; ten of 23 immunoglobulin recipients improved compared with three of 26 placebo recipients. An NADH crossover trial had 33 completers and 26 analysed; 8/26 attained a 10% improvement compared with 2/26 on placebo. Harms included up to 15% withdrawing from active antidepressant treatment because of adverse drug effects, and IgG adverse effects in up to 82% of trial participants.